spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PROSTASCINT 

 HSMN NewsFeed - 18 Dec 2017
Aytu BioScience Announces Appointment of David Green as Chief Financial Officer
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 26 Oct 2017
Aytu BioScience Provides Quarterly Update on the Natesto(R) U.S. Launch
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 3 Oct 2017
Aytu BioScience Announces International Distribution Agreement for Fiera(R) in Japan
Biopharmaceuticals Urology Distribution
 HSMN NewsFeed - 13 Jul 2017
Aytu BioScience Expands MiOXSYS(R) Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe
Diagnostics Urology Distribution
 HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Devices Urology Product Launch
 HSMN NewsFeed - 27 Jan 2016
Aytu BioScience Announces Additions to Board of Directors
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Feb 2012
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Mar 2010
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2009
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2008
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Mar 2008
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Nov 2007
Cytogen Announces Executive Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2007
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2007
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
Biopharmaceuticals Radiology Oncology
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Cytogen Appoints Kevin Bratton New Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Oct 2006
Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy
 HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
Diagnostics Urology Oncology
 HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology
 HSMN NewsFeed - 8 May 2006
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 61

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 61 additional stories matching:
PROSTASCINT
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.